Abstract
Background: Bone marrow stem/progenitor cells seem to be effective in liver regeneration after tissue injury. Aim: To evaluate the feasibility and safety of the mobilization and reinfusion of CD133+ stem/progenitor cells in patients with end-stage liver disease. Methods: Autologous CD133+ stem/progenitor cells, mobilized with granulocyte-colony stimulating factor, were collected by leukapheresis and reinfused at increasing doses through the hepatic artery starting from 5 × 104/kg up to 1 × 106/kg. Results: 16 subjects with Model for End-stage Liver Disease (MELD) score between 17 and 25 were enrolled, 14 mobilized an adequate number of CD133+ stem/progenitor cells and 12 were reinfused. No severe adverse events related to the procedure were reported. MELD score significantly worsened during mobilization in Child Turcotte Pugh-C patients. A significant improvement of liver function was observed 2 months after reinfusion (MELD 19.5 vs 16; P = 0.045). Overall, 5 patients underwent liver transplantation within 12 months from reinfusion and 2 died because of progressive liver failure. Conclusions: CD133+ stem/progenitor cells reinfusion in patients with end-stage liver disease is feasible and safe. A worsening of liver function was observed during mobilization in Child Turcotte Pugh-C patients. The temporary improvement of MELD score after reinfusion suggests that stem cells therapy may be a "bridge to transplant" approach for these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1059-1066 |
| Number of pages | 8 |
| Journal | Digestive and Liver Disease |
| Volume | 47 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 1 2015 |
Fingerprint
Keywords
- Cirrhosis
- Haematopoietic stem/progenitor cells
- Regenerative medicine
- Stem cell therapy
ASJC Scopus subject areas
- Medicine(all)
- Hepatology
- Gastroenterology
Cite this
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease : A phase I clinical trial. / Andreone, Pietro; Catani, Lucia; Margini, Cristina; Brodosi, Lucia; Lorenzini, Stefania; Sollazzo, Daria; Nicolini, Benedetta; Giordano, Rosaria; Montemurro, Tiziana; Rizzi, Simonetta; Dan, Elisa; Giudice, Valeria; Viganò, Mariele; Casadei, Andrea; Foschi, Francesco G.; Malvi, Deborah; Bernardi, Mauro; Conti, Fabio; Lemoli, Roberto M.
In: Digestive and Liver Disease, Vol. 47, No. 12, 01.12.2015, p. 1059-1066.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease
T2 - A phase I clinical trial
AU - Andreone, Pietro
AU - Catani, Lucia
AU - Margini, Cristina
AU - Brodosi, Lucia
AU - Lorenzini, Stefania
AU - Sollazzo, Daria
AU - Nicolini, Benedetta
AU - Giordano, Rosaria
AU - Montemurro, Tiziana
AU - Rizzi, Simonetta
AU - Dan, Elisa
AU - Giudice, Valeria
AU - Viganò, Mariele
AU - Casadei, Andrea
AU - Foschi, Francesco G.
AU - Malvi, Deborah
AU - Bernardi, Mauro
AU - Conti, Fabio
AU - Lemoli, Roberto M.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Bone marrow stem/progenitor cells seem to be effective in liver regeneration after tissue injury. Aim: To evaluate the feasibility and safety of the mobilization and reinfusion of CD133+ stem/progenitor cells in patients with end-stage liver disease. Methods: Autologous CD133+ stem/progenitor cells, mobilized with granulocyte-colony stimulating factor, were collected by leukapheresis and reinfused at increasing doses through the hepatic artery starting from 5 × 104/kg up to 1 × 106/kg. Results: 16 subjects with Model for End-stage Liver Disease (MELD) score between 17 and 25 were enrolled, 14 mobilized an adequate number of CD133+ stem/progenitor cells and 12 were reinfused. No severe adverse events related to the procedure were reported. MELD score significantly worsened during mobilization in Child Turcotte Pugh-C patients. A significant improvement of liver function was observed 2 months after reinfusion (MELD 19.5 vs 16; P = 0.045). Overall, 5 patients underwent liver transplantation within 12 months from reinfusion and 2 died because of progressive liver failure. Conclusions: CD133+ stem/progenitor cells reinfusion in patients with end-stage liver disease is feasible and safe. A worsening of liver function was observed during mobilization in Child Turcotte Pugh-C patients. The temporary improvement of MELD score after reinfusion suggests that stem cells therapy may be a "bridge to transplant" approach for these patients.
AB - Background: Bone marrow stem/progenitor cells seem to be effective in liver regeneration after tissue injury. Aim: To evaluate the feasibility and safety of the mobilization and reinfusion of CD133+ stem/progenitor cells in patients with end-stage liver disease. Methods: Autologous CD133+ stem/progenitor cells, mobilized with granulocyte-colony stimulating factor, were collected by leukapheresis and reinfused at increasing doses through the hepatic artery starting from 5 × 104/kg up to 1 × 106/kg. Results: 16 subjects with Model for End-stage Liver Disease (MELD) score between 17 and 25 were enrolled, 14 mobilized an adequate number of CD133+ stem/progenitor cells and 12 were reinfused. No severe adverse events related to the procedure were reported. MELD score significantly worsened during mobilization in Child Turcotte Pugh-C patients. A significant improvement of liver function was observed 2 months after reinfusion (MELD 19.5 vs 16; P = 0.045). Overall, 5 patients underwent liver transplantation within 12 months from reinfusion and 2 died because of progressive liver failure. Conclusions: CD133+ stem/progenitor cells reinfusion in patients with end-stage liver disease is feasible and safe. A worsening of liver function was observed during mobilization in Child Turcotte Pugh-C patients. The temporary improvement of MELD score after reinfusion suggests that stem cells therapy may be a "bridge to transplant" approach for these patients.
KW - Cirrhosis
KW - Haematopoietic stem/progenitor cells
KW - Regenerative medicine
KW - Stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=84983146118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983146118&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2015.08.018
DO - 10.1016/j.dld.2015.08.018
M3 - Article
VL - 47
SP - 1059
EP - 1066
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 12
ER -